What we do

We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Pharmaceuticals business

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines.

We currently focus on developing new medicines in respiratory, HIV, oncology and immuno-inflammation; with an R&D approach focussed on science related to the immune system, use of genetics and advanced technologies.

Since the invention of our first asthma treatment in the 1960s, we have invested more in respiratory research than any other company worldwide and we remain committed to providing new treatment options for respiratory patients. 

Our pharmaceutical manufacturing plant in Melbourne’s outer-east is GSK’s largest manufacturing facility in the Southern Hemisphere. Our Boronia site is also our fourth-largest sterile facility housing a state-of-the-art Blow-Fill-Seal production line that runs 24 hours a day. Blow-Fill-Seal uses innovative technology for advanced antiseptic liquid medicines. Products manufactured this facility are exported to over 30 markets around the world.

Our HIV medicines are managed through ViiV Healthcare, a joint venture between GSK, Pfizer and Shionogi. ViiV Healthcare Australia has been involved in supporting research through investigator initiated clinical studies and operates its sales and marketing function from GSK’s Abbotsford office in Melbourne.

Read more about our pharmaceutical business here.

Vaccines business

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.

In Australia our vaccines portfolio helps prevent illnesses such as hepatitis, rotavirus and HPV infections, diphtheria, tetanus, whooping cough, measles, mumps, rubella, bacterial meningitis and influenza

We are the primary supplier of childhood vaccines to the National Immunisation Program (NIP) in Australia, providing protection against potentially life threatening diseases like polio, measles, mumps and rubella to nearly 4 million children each year.

Read more about how we manufacture vaccines here.

Consumer Healthcare business

Our Consumer Healthcare business develops and markets consumer preferred and expert recommended brands in the Oral health, Pain relief, Respiratory, Nutrition/gastro-intestinal and Skin health categories. It has a portfolio of some of the world’s most trusted and best selling brands which includes Panadol, Voltaren, Sensodyne, Polident and Otrivin.

We are one of the world’s leading over-the-counter (OTC) medicines companies. We hold number one positions in OTC medicines across 36 markets, and are market leaders in specialist oral care. Our portfolio of loved and trusted brands is underpinned by science.

Our marketplace

Today, people are taking an increasingly active role in managing their own health. This is being fuelled by an emerging global middle class, rising healthcare costs and ageing populations.

Our strategy

Our strategy is to combine the best of our pharmaceutical and Fast Moving Consumer Goods (FMCG) capabilities to become the first and best Fast Moving Consumer Healthcare Company driven by science and values.

To do this we are focussed on building strong global brands, relentless innovation, best in class interactions with retailers, healthcare professionals and shoppers, the highest quality products at the right time and cost, and talented committed people.

Research for product innovation

Our business is built on science and this research heritage contributes to the development of our Consumer Healthcare products, giving us a unique advantage over our competition. 

Today, we are using science to speed up the time to develop new product innovations, make them more accessible to the people who need them, and to develop benefits our consumers value, ultimately growing our business.

At the same time, we continue to ensure we meet all regulatory requirements for testing, approval, manufacturing, labelling and marketing of our products.

Our Australian Consumer Healthcare business is part of the GSK Open Innovation programme – our global campaign to support new innovations to promote change beyond GSK by sharing expertise, resources, intellectual property and know-how with the broader scientific community.

To find out more about how our Open Innovation program is creating positive change around the world, click here.


Our Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Our portfolio is made up of both patent-protected and off patent medicines.


Our Vaccines business is one of the largest in the world, producing paediatric and adult vaccines against a range of infectious diseases. In 2014, we distributed more than 800 million doses to 170 countries, of which over 80% were supplied to developing countries.

Consumer Healthcare

Our Consumer Healthcare business develops and markets a range of products in the areas of: Pain Relief, Respiratory, Oral Health, Nutrition/Gastro Intestinal and Skin Health.